Novel therapies in the treatment of atopic dermatitis
Connie S Zhong, Sarina B Elmariah
Seminars in Cutaneous Medicine and Surgery 2018, 37 (3): 190-197
Atopic dermatitis (AD) is a common cutaneous condition characterized by epidermal barrier disruption, severe skin inflammation, and pruritus. As a result of our growing understanding of disease pathogenesis, the therapeutic armamentarium to manage AD is rapidly expanding. Moving beyond broadly immunosuppressive agents, newer therapies for AD offer more targeted immunomodulation in the forms of phosphodiesterase 4 inhibitors, Janus kinase inhibitors, and anticytokine monoclonal antibodies. While such therapies are generally considered safer than traditional immunosuppressive agents that have been used off label for AD for decades, they are not without risk entirely. In some cases, potential side effects may be difficult to manage. This review summarizes current views on AD pathogenesis and discusses these novel and emerging therapies, including a discussion of the mechanisms of action, potential side effects, and limitations of current clinical trials for each drug. While the rapid and prolific expansion of therapies to treat AD is encouraging, additional studies are needed to adequately evaluate the long-term safety, efficacy, and generalizability among different age groups and disease subtypes.
Atopic dermatitis treatment: Current state of the art and emerging therapies.
Current and emerging topical therapies for atopic dermatitis.
Atopic dermatitis: the new frontier.
Adult atopic dermatitis: new and emerging therapies.
Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies.
Therapy of atopic eczema.
New era of biologic therapeutics in atopic dermatitis.
Therapeutic pipeline for atopic dermatitis: End of the drought?
Adjunctive Management of Itch in Atopic Dermatitis.